Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies

Inclusion Criteria:

* Patients with hematologic malignancies that have relapsed after HLA-A, -B, -C, and-DRBI matched allogeneic hematopoietic stem cell transplantation
* At least 2 months following hematopoietic stem cell transplantation
* Off any systemic immunosuppressive medication for treatment or prevention of GVHD, for a minimum of 2 weeks prior to study entry
* Recipient with donor chimerism of 20% or greater within 6 weeks prior to DLI
* Patient with less than 50% bone marrow involvement (% cellularity) and less than 5cm lymph nodes, in the 6 weeks prior to DLI
* 18 years of age or older
* ECOG Performance Status score 0-2
* Prior stem cell donor is medically fit to undergo leukapheresis procedure

Exclusion Criteria:

* Relapsed CML in chronic phase
* Prior donor lymphocyte infusion or other immunotherapy treatment within 8 weeks prior to enrollment
* Chemotherapy within 4 weeks prior to enrollment
* Clinically significant and active autoimmune disease in donor or patient. This is defined as autoimmune disease resulting in organ dysfunction and/or requiring systemic therapy
* Evidence of active acute or chronic GVHD
* Uncontrolled infection